VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent, methods, compositions and kits having a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes at least one or a plurality of disease agents that are toxins, for example at least one of a Botulinum toxin or an Anthrax toxin.
1. A recombinant binding protein that specifically binds to a Bacillus anthracis toxin, wherein the binding protein comprises an amino acid sequence selected from SEQ ID NO: 81, SEQ ID NO: 93, SEQ ID NO: 13, SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 15, SEQ ID NO: 103, SEQ ID NO: 105, or a combination thereof.
2. The binding protein according to claim 1 , which specifically binds to at least one of an Anthrax surface generated protective antigen (PA), an Anthrax lethal toxin (LT), or an Anthrax edema toxin (ET) of B. anthracis.
3. The binding protein according to claim 2 , wherein the binding protein inhibits or prevents endocytosis of the toxin.
4. The binding protein according to claim 1 , wherein the binding protein is heteromultimeric and comprises a plurality of non-identical binding regions, wherein each binding region specifically binds to a non-overlapping portion of the Bacillus anthracis toxin.
5. The binding protein according to claim 1 , wherein the binding protein further comprises at least one of a tag epitope that is specifically bound by an anti-tag antibody and a linker that separates binding regions of the binding protein, wherein the linker comprises a peptide or a protein.
6. The binding protein of claim 1 , wherein the binding protein comprises an amino acid sequence selected from SEQ ID NO: 81, SEQ ID NO: 93, SEQ ID NO: 13, or a combination thereof.
7. A composition comprising the binding protein of claim 1 .